Status:
COMPLETED
Efficacy of Lithium Against Chemotherapy Induced Neutropenia in Breast Cancer Patients
Lead Sponsor:
Al-Azhar University
Conditions:
Neutropenia
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
Using Lithium Carbonate to decrease incidence of neutropenia caused by using chemotherapy regimen in breast cancer patients.
Detailed Description
Introduction: Cytotoxic chemotherapy predictably suppresses the hematopoietic system, impairing host protective mechanisms. Neutropenia is the most serious hematologic toxicity of cancer chemotherapy...
Eligibility Criteria
Inclusion
- 1\. All patients presented with breast cancer documented by pathological reports stage I, II and III.
Exclusion
- Patients receiving cardiac medication such as diuretics.
- Patients on sodium-restricted diet (to avoid lithium toxicity).
- Stage IV with expected short overall survival.
- Patients with blood or bone marrow cancer (to prevent interference).
- Patients with hepatic and renal impairment.
- Patient with untreated hypothyroidism.
- Pregnant and breast feeding patients.
Key Trial Info
Start Date :
August 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05221593
Start Date
August 1 2020
End Date
June 1 2022
Last Update
October 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Al-Azhar University
Cairo, Non-US/Non-Canadian, Egypt, 11765